Peter Attia Longevity Hypothesized Full Protocol

Who Is Peter Attia and Why Does His Protocol Matter?

Peter Attia is a Stanford- and Johns Hopkins-trained physician who left surgical oncology to focus on the applied science of longevity. His weekly podcast "The Drive" regularly places in the top 1% of health podcasts globally, and his 2023 book "Outlive: The Science and Art of Longevity" spent months on the New York Times bestseller list. Because Attia discusses his own labs, interventions, and reasoning in unusual depth, his self-disclosed regimen serves as one of the most detailed publicly available examples of what a clinically trained longevity physician actually does personally.

One critical note before reading further: Attia has repeatedly said that his personal choices reflect his individual risk tolerance, specific biomarkers, and medical history. He does not recommend that listeners copy his regimen. This article is a journalistic synthesis, not a prescription template.

Attia's "Medicine 3.0" Framework

Attia describes "Medicine 3.0" as a shift from reactive disease treatment toward proactive, probabilistic risk reduction. In "Outlive," he argues that the four major causes of premature death (cardiovascular disease, cancer, neurodegenerative disease, and metabolic dysfunction) share decades-long pre-clinical trajectories, and that early intervention on modifiable risk factors offers far greater life-years gained than late-stage treatment.

This framework shapes every intervention below. Each tool is chosen because Attia believes it meaningfully changes his trajectory on one or more of those four disease vectors.

Public Disclosure vs. Confirmed Record

Every specific intervention listed in this article comes from at least one of these primary sources: episodes of "The Drive" podcast, the text of "Outlive" (2023), Attia's own social media posts, or on-record interviews with named journalists. Where a detail is inferred rather than directly stated, this article uses the phrase "Attia has implied" or "based on context." Speculation is labeled as such.

Exercise: The Intervention Attia Ranks Above All Others

Attia has stated across multiple podcast episodes that if he could only keep one intervention, it would be exercise. He cites a 2022 analysis published in the Journal of the American College of Cardiology showing that low cardiorespiratory fitness carries a higher all-cause mortality hazard ratio than smoking, hypertension, or type 2 diabetes [1].

Zone 2 Cardio

Attia targets roughly 3 to 4 hours of Zone 2 aerobic training per week, typically split across four sessions. Zone 2 is defined as the highest intensity at which blood lactate remains below approximately 2 mmol/L, an intensity many athletes sustain through brisk cycling or rowing while still holding a conversation. Attia has used lactate meters to calibrate this threshold personally rather than relying on heart-rate approximations alone.

The metabolic rationale centers on mitochondrial density and fat-oxidation capacity. A 2017 paper in Cell Metabolism demonstrated that endurance exercise training increases mitochondrial biogenesis via PGC-1alpha upregulation, a pathway relevant to both metabolic health and cellular aging [2].

Strength and Stability Training

Four days per week, Attia performs resistance training with a strong emphasis on functional movements: hip hinges, loaded carries, single-leg work, and grip strength. He has cited grip strength and VO2 max as the two biomarkers he tracks most aggressively, both of which are independently associated with all-cause mortality in large cohorts [3].

Attia has discussed training for what he calls the "centenarian decathlon": the set of physical tasks he wants to perform at age 100, such as carrying groceries, getting off the floor unassisted, and playing with grandchildren. He works backward from those targets to set current training minimums.

VO2 Max as a Priority Metric

In episodes of "The Drive," Attia has stated his goal is to maintain a VO2 max in at least the 75th percentile for his age group for the rest of his life. A 2018 JAMA Network Open study (N=122,007) found that cardiorespiratory fitness was inversely associated with long-term mortality, with the highest fitness group showing a 5-fold lower mortality risk compared to the least fit [4].

Nutrition: High Protein, Variable Eating Windows

Attia's dietary approach has evolved publicly and he has been transparent about that evolution. He previously practiced extended time-restricted eating and periodic prolonged fasting; he has since moved away from prolonged fasting after reflecting on its impact on muscle mass preservation.

Protein Target

The most consistent dietary position Attia holds is a high protein intake. He targets approximately 1 gram of protein per pound of body weight per day, equating to roughly 160 to 180 grams daily for him personally. This aligns with evidence suggesting that older adults require 1.2 to 1.6 g/kg/day to preserve lean mass, above the 0.8 g/kg/day RDA [5].

Continuous Glucose Monitoring

Attia has worn a continuous glucose monitor (CGM) regularly and discussed CGM data extensively on his podcast. He uses it not to manage diagnosed diabetes but to observe individual glycemic responses to specific foods, stress, and poor sleep. A CGM provides glucose readings every 5 to 15 minutes, allowing real-time feedback on metabolic behavior that fasting glucose or HbA1c cannot capture.

Alcohol

Attia has publicly disclosed reducing his alcohol intake to near zero in recent years, citing evidence linking even moderate alcohol consumption to increased cancer risk. A 2018 Lancet analysis (N=599,912) found no safe level of alcohol consumption with respect to overall health, with cancer risk rising linearly from zero drinks per week [6].

Sleep: The Non-Negotiable

Attia ranks sleep alongside exercise as the highest-return health behavior. He targets an 8-hour sleep opportunity each night and tracks sleep stages with a wearable device. He has spoken about his own history of poor sleep and the interventions he used to address it, including strict temperature control (bedroom at approximately 67 to 68 degrees Fahrenheit), eliminating alcohol, and, at certain points, low-dose trazodone or other pharmacological support.

Why Sleep Affects Longevity Pathways

Short sleep duration is associated with increased amyloid beta accumulation in the brain, a finding relevant to Alzheimer's disease risk. A 2017 study in Nature Communications (N=10,561) found that both short sleep (<6 hours) and long sleep (>9 hours) were independently associated with cognitive decline [7]. Attia discusses the glymphatic system and sleep's role in cerebral waste clearance as a primary reason he treats sleep disruption as a medical emergency rather than a lifestyle preference.

Medications: What Attia Has Disclosed

This section covers only interventions Attia has directly discussed in public forums. None of the following should be interpreted as HealthRX confirming his current prescriptions or recommending these agents for general use.

Rapamycin

Rapamycin (sirolimus) is the drug most associated with Attia's name in the longevity space. He has disclosed taking rapamycin intermittently, typically describing a weekly dose rather than daily dosing. Rapamycin inhibits mTORC1, a nutrient-sensing kinase whose suppression has consistently extended lifespan in model organisms. The Interventions Testing Program (ITP), a multi-site NIA-funded trial using genetically diverse mice, found that rapamycin initiated late in life extended median lifespan by 9% in males and 14% in females [8].

Human data for rapamycin as a longevity agent remains limited. A 2014 study in Science Translational Medicine (N=218 elderly adults) used the rapamycin analog everolimus and showed improved influenza vaccine response, suggesting mTORC1 inhibition may partially reverse immune aging [9]. The PEARL trial is currently recruiting to assess rapamycin's effects on aging biomarkers in healthy middle-aged adults; results are not yet published.

Attia has been explicit that his use of rapamycin is experimental. He has stated that he accepts the uncertainty and monitors for known adverse effects including impaired wound healing, dyslipidemia, and potential immunosuppression.

Metformin: A Drug Attia Stopped Taking

Attia used metformin for years, citing the TAME (Targeting Aging with Metformin) trial rationale. He then publicly stopped taking it after data suggested metformin may blunt the beneficial adaptations to exercise training, specifically the mitochondrial biogenesis response. A 2019 Nature Aging study (N=53) found that metformin attenuated the increase in mitochondrial respiration normally seen after aerobic exercise training [10]. Given his high exercise volume, Attia concluded the trade-off was not in his favor.

This is an important example of Attia updating his protocol based on emerging evidence, a behavior he discusses explicitly as central to his approach.

Testosterone Replacement Therapy (TRT)

Attia has disclosed that he takes testosterone replacement therapy. He has discussed TRT broadly on his podcast in the context of male hormonal health, hypogonadism diagnosis criteria, and the nuances of total versus free testosterone measurement. He has implied that his own testosterone levels were in a range he found suboptimal before starting TRT, though he has not shared specific lab values publicly.

TRT in men with confirmed hypogonadism improves lean mass, bone density, and in some studies, cardiovascular outcomes. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism and high cardiovascular risk did not increase the rate of major adverse cardiovascular events compared to placebo [11].

Low-Dose Naltrexone (LDN)

Attia has mentioned low-dose naltrexone in the context of its potential anti-inflammatory and immune-modulating properties. LDN (typically 1.5 to 4.5 mg/day, far below the 50 mg dose used for opioid dependence) is thought to transiently block opioid receptors, triggering an upregulation of endogenous opioid production and modulation of microglial activity. Evidence remains preliminary; most human data comes from small trials in fibromyalgia, Crohn's disease, and multiple sclerosis [12]. Attia has framed LDN as a low-risk exploratory intervention rather than a cornerstone of his protocol.

Statins and PCSK9 Inhibition

Attia is an outspoken advocate for aggressive LDL-C lowering, particularly ApoB reduction, as a cardiovascular risk reduction strategy. He has stated that he takes a statin and has discussed PCSK9 inhibitors with interest. His public position, supported by Mendelian randomization data and large RCT meta-analyses, is that lower lifetime ApoB exposure translates directly to lower cardiovascular event rates [13].

He has cited the 2010 Cholesterol Treatment Trialists meta-analysis showing that each 1 mmol/L reduction in LDL-C produces approximately a 22% relative risk reduction in major cardiovascular events [14].

Supplements: The Attia Stack

The following framework synthesizes Attia's most consistently mentioned supplements across episodes of "The Drive" published between 2019 and 2024. Doses listed are those he has stated personally or implied through discussion of the relevant literature.

Creatine Monohydrate

Attia takes creatine monohydrate, typically 5 g/day. Beyond its well-established role in power output, creatine has emerging evidence for cognitive and neuroprotective effects. A 2022 Cochrane-adjacent systematic review in Nutrients found creatine supplementation improved upper-body muscular endurance in aging adults [15].

Omega-3 Fatty Acids (EPA/DHA)

Attia targets a high dose of combined EPA and DHA, often in the range of 2 to 4 grams per day from either fish oil or a prescription formulation. The REDUCE-IT trial (N=8,179) showed that icosapentaenoic acid (EPA) 4 g/day as Vascepa reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides [16].

Magnesium

Attia has discussed using magnesium threonate for sleep quality and cognitive health, alongside other magnesium forms for general repletion. Approximately 45% of Americans do not meet the Estimated Average Requirement for magnesium from diet alone, according to NHANES data analyzed by the NIH Office of Dietary Supplements [17].

Vitamin D and Vitamin K2

Attia monitors 25-hydroxyvitamin D levels and targets a serum concentration in the range of 40 to 60 ng/mL. He pairs vitamin D supplementation with vitamin K2 based on mechanistic reasoning about calcium metabolism. The USPSTF does not currently recommend universal vitamin D supplementation for adults without deficiency, though the evidence for supplementation in confirmed deficient individuals is stronger [18].

Protein Supplementation

Attia uses whey protein or other complete protein sources to hit his daily gram targets when whole food intake falls short. He has specifically discussed leucine content as a key driver of muscle protein synthesis signaling through the mTORC1 pathway.

Cognitive Health and Alzheimer's Risk Reduction

Attia has an APOE4 allele status discussion history. He disclosed publicly that he has tested his APOE genotype and has shared that this knowledge shapes his approach to metabolic health, sleep, omega-3 intake, and exercise, all of which have mechanistic or epidemiological links to Alzheimer's risk reduction. Carriers of two APOE4 alleles carry up to a 12-fold increased lifetime risk of Alzheimer's compared to APOE3/3 individuals, per data from the National Institute on Aging [19].

Attia has been deliberate about not publicly disclosing his specific APOE4 status (one versus two copies), citing privacy, though he has confirmed awareness of his genotype.

Cardiovascular Risk as a Proxy for Brain Health

One of Attia's consistent themes is that vascular health and brain health are deeply linked. He frequently references data showing that midlife cardiovascular risk factors, including hypertension, insulin resistance, and dyslipidemia, are strong predictors of late-life cognitive decline. The FINGER trial (N=1,260), a randomized controlled trial published in The Lancet, demonstrated that a multi-domain intervention covering diet, exercise, cognitive training, and vascular risk monitoring significantly improved cognitive performance over 2 years in at-risk older adults [20].

Biomarker Tracking: How Attia Measures Progress

Attia performs comprehensive laboratory testing multiple times per year. He has described panels that include ApoB, Lp(a), fasting insulin, HOMA-IR, HbA1c, a full lipid panel, liver enzymes, inflammatory markers (hsCRP, IL-6), complete blood count, testosterone (total and free), SHBG, IGF-1, DHEA-S, complete metabolic panel, and DEXA scans for body composition and bone density.

He has stated that tracking Lp(a) is particularly important because elevated Lp(a) is a genetically determined, largely LDL-independent cardiovascular risk factor affecting approximately 20% of the global population, and it is under-tested in standard clinical practice [21].

Attia uses DEXA scans for both bone mineral density and visceral adiposity estimation, viewing visceral fat as a more relevant metabolic risk marker than BMI <27 cutoffs or body weight alone.

Mental Health and Emotional Wellbeing

In more recent episodes of "The Drive" and in public interviews, Attia has disclosed undergoing intensive psychotherapy, including a multi-week residential program at Hoffman Institute. He has framed emotional health as equally important to physical longevity, arguing that extending lifespan without addressing relationships and psychological suffering produces hollow outcomes. This represents a meaningful evolution in his public messaging since the early years of "The Drive."